ESMO: Cardiff Oncology Falls Despite Onvansertib’s Broad Potential In KRAS-Mutant CRC

Phase II Trial To Initiate In Q4; Data In 2024

 
• By Mandy Jackson
  
Anatomy of human body with digestive system
Onvansertib generated responses across several KRAS mutations in CRC • Source: Shutterstock

More from Clinical Trials

More from R&D